Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.65 |
| ▸ | BACE1 | P56817 | 13/20 | 0.65 |
| ▸ | BCHE | P06276 | 12/20 | 0.65 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189114 | 1.00 | ACHE (0.65) | ACHEBACE1BCHEFUCA1CXCR4 | |
| SCHEMBL12506909 | 1.00 | ACHE (0.65) | ACHEBACE1BCHEFUCA1CXCR4 | |
| SCHEMBL2190637 | 1.00 | ACHE (0.65) | ACHEBACE1BCHEFUCA1CXCR4 | |
| SCHEMBL2191531 | 0.89 | ACHE (0.65) | ACHEBACE1BCHEFUCA1CXCR4 | |
| SCHEMBL12506912 | 0.89 | ACHE (0.65) | ACHEBACE1BCHEFUCA1CXCR4 | |
| SCHEMBL16691751 | 0.89 | ACHE (0.65) | ACHEBACE1BCHEFUCA1CXCR4 | |
| SCHEMBL2187469 | 0.87 | FUCA1 (0.53) | ACHEBACE1BCHEFUCA1ALDH1A1 | |
| SCHEMBL2187482 | 0.87 | FUCA1 (0.53) | ACHEBACE1BCHEFUCA1ALDH1A1 | |
| SCHEMBL2187476 | 0.87 | FUCA1 (0.53) | ACHEBACE1BCHEFUCA1ALDH1A1 | |
| SCHEMBL13229622 | 0.87 | FUCA1 (0.63) | ACHEBACE1BCHEFUCA1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | ACHE 3409/4885BACE1 2080/4885BCHE 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.